Physician profile
Peter Namkoong
NPI 1154385649
$3,796.76
in general payments reported to CMS, 2019-2025
26 companies · $53.40 in 2025
The $53.40 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $381 · 2021: $797 · 2022: $1,101 · 2023: $766 · 2024: $29.75 · 2025: $53.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $849.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,383.84 | 2019-2023 | |
| Novo Nordisk INC | $262.61 | 2019-2023 | Wegovy |
| Exeltis, USA INC. | $240.00 | 2021-2023 | Slynd, Tyblume |
| Mayne Pharma Commercial LLC | $229.87 | 2021-2023 | |
| Hologic Sales and Service, LLC | $214.78 | 2019-2025 | Novasure, Omni Hysteroscope, Acessa Provu System |
| Myovant Sciences INC. | $204.36 | 2021-2022 | |
| Therapeuticsmd, INC. | $176.74 | 2019-2022 | |
| Coopersurgical, INC. | $164.40 | 2019-2023 | Paragard T 380a |
| Pfizer INC. | $145.16 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.06 | 2019-2022 | |
| Avion Pharmaceuticals | $96.39 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $92.21 | 2023 | Myfembree |
| Lupin INC. | $68.78 | 2019-2020 | |
| Astellas Pharma US INC | $68.31 | 2023 | Veozah, Myrbetriq |
| Amag Pharmaceuticals, INC. | $56.23 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $50.36 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $40.05 | 2019 | |
| Millicent US INC | $34.25 | 2019 | |
| Bausch Health US, LLC | $30.34 | 2020 | |
| Lilly USA, LLC | $29.75 | 2024 | Zepbound |
| Organon LLC | $21.06 | 2022 | |
| Idorsia Pharmaceuticals US INC | $21.01 | 2022 | |
| Channel Medsystems, INC. | $19.75 | 2022-2023 | |
| Medicem INC. | $17.45 | 2020 | |
| Sage Therapeutics, LLC | $11.11 | 2019 | |
| Ferring Pharmaceuticals INC. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Namkoong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.